PMC:7426526 / 64855-65362 JSONTXT

{"project":"TEST0","denotations":[{"id":"32849491-202-209-3396639","span":{"begin":386,"end":389},"obj":"[\"28057014\"]"},{"id":"32849491-110-117-3396640","span":{"begin":502,"end":505},"obj":"[\"28057014\"]"}],"text":"Additional studies (Table 9) are ongoing for the treatment of relapsed or refractory AML (NCT03473457), relapsed or late staged sarcoma (NCT03356782), as well as glioma (NCT03423992). A case study of a patient receiving CD133-directed CAR T-cells after previous chemo- and radiotherapy as well as EGFR-directed CAR T-cell therapy reported a partial response for a period of 4.5 months (569). However, severe toxicities affecting the skin, the oral mucosa, and the gastrointestinal tract were reported (569)."}

{"project":"MyTest","denotations":[{"id":"32849491-28057014-34971019","span":{"begin":386,"end":389},"obj":"28057014"},{"id":"32849491-28057014-34971020","span":{"begin":502,"end":505},"obj":"28057014"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Additional studies (Table 9) are ongoing for the treatment of relapsed or refractory AML (NCT03473457), relapsed or late staged sarcoma (NCT03356782), as well as glioma (NCT03423992). A case study of a patient receiving CD133-directed CAR T-cells after previous chemo- and radiotherapy as well as EGFR-directed CAR T-cell therapy reported a partial response for a period of 4.5 months (569). However, severe toxicities affecting the skin, the oral mucosa, and the gastrointestinal tract were reported (569)."}

{"project":"2_test","denotations":[{"id":"32849491-28057014-34971019","span":{"begin":386,"end":389},"obj":"28057014"},{"id":"32849491-28057014-34971020","span":{"begin":502,"end":505},"obj":"28057014"}],"text":"Additional studies (Table 9) are ongoing for the treatment of relapsed or refractory AML (NCT03473457), relapsed or late staged sarcoma (NCT03356782), as well as glioma (NCT03423992). A case study of a patient receiving CD133-directed CAR T-cells after previous chemo- and radiotherapy as well as EGFR-directed CAR T-cell therapy reported a partial response for a period of 4.5 months (569). However, severe toxicities affecting the skin, the oral mucosa, and the gastrointestinal tract were reported (569)."}